000134852 001__ 134852
000134852 005__ 20240229105044.0
000134852 0247_ $$2doi$$a10.1159/000479007
000134852 0247_ $$2pmid$$apmid:29166639
000134852 0247_ $$2ISSN$$a0031-2959
000134852 0247_ $$2ISSN$$a0304-3568
000134852 0247_ $$2ISSN$$a0371-487X
000134852 0247_ $$2ISSN$$a1015-2008
000134852 0247_ $$2ISSN$$a1423-0291
000134852 037__ $$aDKFZ-2018-00642
000134852 041__ $$aeng
000134852 082__ $$a610
000134852 1001_ $$aHeller, Martina$$b0
000134852 245__ $$aAPOBEC3A Expression in Penile Squamous Cell Carcinoma.
000134852 260__ $$aBasel$$bKarger$$c2018
000134852 3367_ $$2DRIVER$$aarticle
000134852 3367_ $$2DataCite$$aOutput Types/Journal article
000134852 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1529306622_16578
000134852 3367_ $$2BibTeX$$aARTICLE
000134852 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000134852 3367_ $$00$$2EndNote$$aJournal Article
000134852 520__ $$aAPOBECs (apolipoprotein B mRNA-editing catalytic polypeptides) are cytidine deaminases that have been implicated in the host defense against viruses by blocking viral replication. They have also been shown to play a role in genome hypermutation in several human cancers. An APOBEC3 hypermutation signature has been discovered in cervical cancer, which is intimately associated with infection by high-risk human papillomaviruses (HPVs). At the same time, HPV genomes themselves are subject to DNA editing by APOBECs. Similar to cervical cancer, a proportion of penile squamous cell carcinomas (SCCs) is etiologically driven by high-risk HPVs, but very little is known about the role of APOBECs in penile SCC development and progression.A series of 34 penile SCCs was analyzed for the expression of APOBEC3A protein by immunohistochemistry. HPV genotyping was carried out using a bead-based multiplex hybridization assay preceded by BSGP5+6+ primer-based amplification.We found a frequent reduction of APOBEC3A protein expression in the invasive parts of the majority of HPV-negative penile SCCs. In contrast, the majority of HPV-positive penile SCCs retained APOBEC3A expression during malignant progression.Our results suggest that APOBEC3A expression is downregulated during progression towards invasiveness in HPV-negative penile SCC, but maintained in HPV-positive penile SCC. How high-risk HPV-infected tumor cells tolerate high APOBEC3A, which appears to exert tumor suppressive functions in HPV-negative penile SCCs, remains to be elucidated.
000134852 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000134852 588__ $$aDataset connected to CrossRef, PubMed,
000134852 7001_ $$0P:(DE-He78)83e1d0ede46be662d4a75f18e2dc7eec$$aPrigge, Elena-Sophie$$b1$$udkfz
000134852 7001_ $$aKaczorowski, Adam$$b2
000134852 7001_ $$0P:(DE-He78)11747cd1dc061b9333c0e3a3ff31bf2f$$avon Knebel Doeberitz, Magnus$$b3
000134852 7001_ $$aHohenfellner, Markus$$b4
000134852 7001_ $$aDuensing, Stefan$$b5
000134852 773__ $$0PERI:(DE-600)1483541-1$$a10.1159/000479007$$gVol. 85, no. 3, p. 169 - 178$$n3$$p169 - 178$$tPathobiology$$v85$$x1423-0291$$y2018
000134852 909CO $$ooai:inrepo02.dkfz.de:134852$$pVDB
000134852 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)83e1d0ede46be662d4a75f18e2dc7eec$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000134852 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)11747cd1dc061b9333c0e3a3ff31bf2f$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000134852 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000134852 9141_ $$y2018
000134852 915__ $$0StatID:(DE-HGF)0400$$2StatID$$aAllianz-Lizenz / DFG
000134852 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000134852 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bPATHOBIOLOGY : 2015
000134852 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000134852 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000134852 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000134852 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000134852 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000134852 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000134852 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000134852 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000134852 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000134852 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000134852 9201_ $$0I:(DE-He78)G105-20160331$$kG105$$lGentherapie von Tumoren$$x0
000134852 980__ $$ajournal
000134852 980__ $$aVDB
000134852 980__ $$aI:(DE-He78)G105-20160331
000134852 980__ $$aUNRESTRICTED